Novo Nordisk Faces Setback in Kidney Disease Drug Trial

Novo Nordisk hoped a new drug, ziltivekimab, would fight chronic kidney disease. The company just finished a big study called ZEUS. The study showed the drug did not hit its main target.

This news is a blow for Novo Nordisk. Experts thought ziltivekimab could bring in a lot of money. It was also meant to help the company grow into new areas.

Despite this, Novo Nordisk has other trials running. These are called Artemis and Hermes. They are testing the same drug for other health issues. These trials could still lead to success for ziltivekimab.

Investors watch these trials closely. The future of ziltivekimab depends on their results. A positive outcome could still help many patients with chronic kidney disease.

Source: FierceBiotech